| Name | Title | Contact Details |
|---|---|---|
John McKeon |
VP of finance | Profile |
Jeffrey Tong |
Chief Executive Officer | Profile |
Samira Shaikhly |
Chief Human Resources Officer | Profile |
Genera Energy provides a robust and integrated biomass supply solution for the advanced biofuels, biopower, and biobased products industries.
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
Uniquely poised as a world class FDA registered outsourcing pharmaceutical manufacturer, Medivant offers the best in the industry when it comes to reliability and management, supply chain transparency, and lower total net cost. *dba Tailstorm Health, Inc. Our vials are made to the exact dosage specification allowing you to achieve a lower net cost of ordering, reducing total waste, and saving you money in the process. Our state of the art manufacturing facility has been completely designed from the ground up with the highest technology available, with full automation, and superior excellence, with highly trained staff experienced in top quality production.
Hatec Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.